Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2026-08-25 21:29:28 ET · period of report 2026-08-21 · accession 0001837798-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 21:29 | 2026-08-21 | AUPH | Robertson Stephen P. | CLO | S - Sale | $16.97 | -21.0K | 600.8K | -3% | -$355.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-21 | S | D | 20,975 | $16.97 | 600,787 | D | — | — | (F1) Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award. (F2) The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 360 common shares that were acquired on May 29, 2026 by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan. |